Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesamorelin in HIV Lipodystrophy
NCT03226821Phase 4Terminated
- Sponsor
- Columbia University
- Start
- Feb 2018
- Primary completion
- Apr 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tesamorelin in HIV-associated lipodystrophy syndrome (HALS), sponsored by Columbia University. Primary endpoint: Hepatic Lipid Content. Started Feb 2018; status: terminated.
02
Drugs
tesamorelin
03
Conditions
HIV-associated lipodystrophy syndrome (HALS)
Beyond the preview
Go deeper on NCT03226821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03226821.